{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T23:18:26Z","timestamp":1756682306474,"version":"3.37.3"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate and update the evidence on the comparative efficacy and safety of antimicrobial drugs regimens for treating pulmonary drug-susceptible tuberculosis (DS-TB).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic review was performed with searches in PubMed and Scopus (PROSPERO-CRD42019141463). We included randomised controlled trials comparing the effect of any antimicrobial regimen lasting at least 2 weeks. The outcomes of interest were culture conversion and incidence of adverse events. Bayesian network meta-analyses and surface under the cumulative ranking curve (SUCRA) analyses were performed. Results were reported as odds ratio with 95% credibility intervals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Fifteen studies were included the meta-analysis (n = 7560 patients). No regimen was statistically more effective than the WHO standard approach (rifampicin, isoniazid, ethambutol, and pyrazinamide). The use of rifapentine 450\u00a0mg instead of rifampicin in the standard regimen demonstrated to be statistically safer than all other options for serious adverse events (e.g. hepatotoxicity, arthralgia) (OR ranging from 0.0 [Crl 0.00\u20130.04] to 0.0 [0.00\u20130.97]; SUCRA probabilities of 10%). Therapies containing rifapentine (Rp1500HEZ, Rp900HEZ) and moxifloxacin (RMEZ, RHMZ) are effective regarding culture conversion, but statistical uncertainty on their safety profile exists.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The WHO standard regimen remains an overall effective and safe alternative for DS-TB. For intensive phase treatments, drugs combinations with rifapentine and moxifloxacin seem to reduce treatment duration while maintaining efficacy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpp\/rgac004","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T20:12:19Z","timestamp":1643746339000},"page":"905-917","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of daily treatments for drug-susceptible pulmonary tuberculosis: a systematic review and network meta-analysis"],"prefix":"10.1093","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-1258","authenticated-orcid":false,"given":"Priscila","family":"Imazu","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences Postgraduate Research Program, Federal University of Paran\u00e1 , Curitiba ,","place":["Brazil"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0244-5049","authenticated-orcid":false,"given":"Josiane M","family":"Santos","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Postgraduate Research Program, Federal University of Paran\u00e1 , Curitiba ,","place":["Brazil"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0944-3321","authenticated-orcid":false,"given":"Francisco","family":"Beraldi-Magalh\u00e3es","sequence":"additional","affiliation":[{"name":"Tropical Medicine Postgraduate Research Program, University of Amazonas , Manaus ,","place":["Brazil"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-9595","authenticated-orcid":false,"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto , Porto ,","place":["Portugal"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-8608","authenticated-orcid":false,"given":"Fernanda S","family":"Tonin","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Postgraduate Research Program, Federal University of Paran\u00e1 , Curitiba ,","place":["Brazil"]},{"name":"H&TRC - Health and Technology Research Center, ESTeSL - Escola Superior de Tecnologia da Sa\u00fade, Instituto Polit\u00e9cnico de Lisboa , Lisbon ,","place":["Portugal"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-4363","authenticated-orcid":false,"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Federal University of Paran\u00e1 , Curitiba ,","place":["Brazil"]}]}],"member":"286","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"2024103012174287100_CIT0001","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1473-3099(15)00499-5","article-title":"The transmission of Mycobacterium tuberculosis in high burden settings","volume":"2","author":"Yates","year":"2016","journal-title":"Lancet Infect Dis"},{"volume-title":"Global Tuberculosis Teport 2019","year":"2019","author":"WHO","key":"2024103012174287100_CIT0002"},{"key":"2024103012174287100_CIT0003","doi-asserted-by":"crossref","first-page":"e0176354","DOI":"10.1371\/journal.pone.0176354","article-title":"Primary multidrug-resistant tuberculosis versus drug-sensitive tuberculosis in non-HIV-infected patients: Comparisons of CT findings","volume":"6","author":"Li","year":"2017","journal-title":"PLoS One"},{"key":"2024103012174287100_CIT0004","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/thoraxjnl-2017-211120","article-title":"Predicting tuberculosis relapse in patients treated with the standard 6-month regimen: an individual patient data meta-analysis","volume":"3","author":"Romanowski","year":"2019","journal-title":"Thorax"},{"key":"2024103012174287100_CIT0005","doi-asserted-by":"crossref","first-page":"e1002595","DOI":"10.1371\/journal.pmed.1002595","article-title":"Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies","volume":"7","author":"Alipanah","year":"2018","journal-title":"PLoS Med"},{"key":"2024103012174287100_CIT0006","doi-asserted-by":"crossref","first-page":"731","DOI":"10.5588\/ijtld.17.0596","article-title":"Interventions to improve adherence to tuberculosis treatment: systematic review and meta-analysis","volume":"7","author":"Muller","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024103012174287100_CIT0007","first-page":"CD012918","article-title":"Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis","volume":"12","author":"Grace","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2024103012174287100_CIT0008","first-page":"CD004795","article-title":"Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)","author":"Ziganshina","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2024103012174287100_CIT0009","doi-asserted-by":"crossref","first-page":"e0145066","DOI":"10.1371\/journal.pone.0145066","article-title":"Effects of fluroquinolones in newly diagnosed, sputum-positive tuberculosis therapy: a systematic review and network meta-analysis","volume":"12","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"2024103012174287100_CIT0010","doi-asserted-by":"crossref","first-page":"e0159827","DOI":"10.1371\/journal.pone.0159827","article-title":"The effectiveness and safety of fluoroquinolone-containing regimen as a first-line treatment for drug-sensitive pulmonary tuberculosis: a systematic review and meta-analysis","volume":"7","author":"Lee","year":"2016","journal-title":"PLoS One"},{"key":"2024103012174287100_CIT0011","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/cid\/cix247","article-title":"Comparing the efficacy of drug regimens for pulmonary tuberculosis: meta-analysis of endpoints in early-phase clinical trials","volume":"1","author":"Bonnett","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024103012174287100_CIT0012","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/CLEP.S16526","article-title":"Multiple treatment comparison meta-analyses: a step forward into complexity","author":"Mills","year":"2011","journal-title":"Clin Epidemiol"},{"key":"2024103012174287100_CIT0013","doi-asserted-by":"crossref","first-page":"943","DOI":"10.18549\/PharmPract.2017.01.943","article-title":"Network meta-analysis: a technique to gather evidence from direct and indirect comparisons","volume":"1","author":"Tonin","year":"2017","journal-title":"Pharm Pract (Granada)"},{"key":"2024103012174287100_CIT0014","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3390\/ijms18020341","article-title":"Combined use of delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis: a systematic review","volume":"18","author":"Migliori","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2024103012174287100_CIT0015","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1093\/cid\/ciy625","article-title":"Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment.","author":"Bolhuis","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024103012174287100_CIT0016","first-page":"Cd012836","article-title":"Linezolid for drug-resistant pulmonary tuberculosis","volume":"3","author":"Singh","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2024103012174287100_CIT0017","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"11","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2024103012174287100_CIT0018","article-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022).","author":"Higgins","year":"2022","journal-title":"Cochrane"},{"key":"2024103012174287100_CIT0019","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024103012174287100_CIT0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2","volume":"4","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"2024103012174287100_CIT0021","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"4","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"2024103012174287100_CIT0022","first-page":"133","article-title":"The attractiveness of network meta-analysis: a comprehensive systematic and narrative review","volume":"2","author":"Greco","year":"2015","journal-title":"Heart Lung Vessel"},{"key":"2024103012174287100_CIT0023","doi-asserted-by":"crossref","first-page":"e0212650","DOI":"10.1371\/journal.pone.0212650","article-title":"Description of network meta-analysis geometry: a metrics design study","volume":"2","author":"Tonin","year":"2019","journal-title":"PLoS One"},{"key":"2024103012174287100_CIT0024","first-page":"1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"7454","author":"Group","year":"2004","journal-title":"BMJ"},{"key":"2024103012174287100_CIT0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/cid\/ciz152","article-title":"A moxifloxacin-based regimen for the treatment of recurrent, drug-sensitive pulmonary tuberculosis: an open-label, randomized, controlled trial","volume":"1","author":"Perumal","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024103012174287100_CIT0026","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1128\/AAC.06125-11","article-title":"Phase II dose-ranging trial of the early bactericidal activity of PA-824","volume":"6","author":"Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103012174287100_CIT0027","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(12)61080-0","article-title":"14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial","volume":"9846","author":"Diacon","year":"2012","journal-title":"Lancet"},{"key":"2024103012174287100_CIT0028","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1128\/AAC.02243-12","article-title":"Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis","volume":"5","author":"Diacon","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103012174287100_CIT0029","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.201410-1801OC","article-title":"Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline","volume":"8","author":"Diacon","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2024103012174287100_CIT0030","doi-asserted-by":"crossref","first-page":"e02012","DOI":"10.1128\/AAC.02012-19","article-title":"Fourteen-day bactericidal activity, safety, and pharmacokinetics of linezolid in adults with drug-sensitive pulmonary tuberculosis","volume":"64","author":"Diacon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103012174287100_CIT0031","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/clinids\/22.5.827","article-title":"Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis","volume":"5","author":"Kennedy","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2024103012174287100_CIT0032","first-page":"108","article-title":"The comparison of six-month and four-month regimens of chemotherapy in the treatment of smear positive pulmonary tuberculosis.","volume":"6","author":"Sharifi-Mood","year":"2006","journal-title":"J. Med. Sci"},{"key":"2024103012174287100_CIT0033","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jiac.2019.05.030","article-title":"Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: a prospective randomized open-label study","volume":"12","author":"Hagiwara","year":"2019","journal-title":"J Infect Chemother"},{"key":"2024103012174287100_CIT0034","first-page":"810","article-title":"Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: a systematic review","volume":"7","author":"Gao","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024103012174287100_CIT0035","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.5588\/ijtld.18.0822","article-title":"Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"12","author":"Lifan","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024103012174287100_CIT0036","article-title":"Addressing the challenges of tuberculosis: a brief historical account","volume":"689","author":"Al-Humadi","year":"2017","journal-title":"Front Pharmacol"},{"key":"2024103012174287100_CIT0037","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(10)60359-9","article-title":"Global tuberculosis drug development pipeline: the need and the reality","volume":"9731","author":"Ma","year":"2010","journal-title":"Lancet"},{"key":"2024103012174287100_CIT0038","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(13)70328-1","article-title":"New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects","volume":"4","author":"Zumla","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2024103012174287100_CIT0039","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-3156.2011.02755.x","article-title":"The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and how can we get out?","volume":"6","author":"van den Boogaard","year":"2011","journal-title":"Trop Med Int Health"},{"key":"2024103012174287100_CIT0040","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1513\/AnnalsATS.201905-394OC","article-title":"Temporal factors and missed doses of tuberculosis treatment. a causal associations approach to analyses of digital adherence data","volume":"4","author":"Stagg","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2024103012174287100_CIT0041","first-page":"CD012918","article-title":"Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis","volume":"12","author":"Grace","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2024103012174287100_CIT0042","doi-asserted-by":"crossref","first-page":"103937","DOI":"10.1016\/j.meegid.2019.103937","article-title":"Evolution of rifampicin treatment for tuberculosis","volume":"74","author":"Grobbelaar","year":"2019","journal-title":"Infect Genet Evol"},{"key":"2024103012174287100_CIT0043","doi-asserted-by":"crossref","first-page":"832","DOI":"10.5588\/ijtld.15.0577","article-title":"A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis","volume":"6","author":"Jindani","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024103012174287100_CIT0044","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201712-2524OC","article-title":"Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial","volume":"5","author":"Velasquez","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024103012174287100_CIT0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"1","author":"Boeree","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2024103012174287100_CIT0046","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1128\/AAC.01918-13","article-title":"Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability","volume":"6","author":"Savic","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103012174287100_CIT0047","first-page":"528","article-title":"Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial","volume":"9332","author":"Benator","year":"2002","journal-title":"Lancet"},{"key":"2024103012174287100_CIT0048","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/clpt.2011.323","article-title":"Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers","volume":"5","author":"Dooley","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2024103012174287100_CIT0049","doi-asserted-by":"crossref","first-page":"8023935","DOI":"10.1155\/2017\/8023935","article-title":"Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications","volume":"2017","author":"Michalak","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"2024103012174287100_CIT0050","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1037\/met0000209","article-title":"The unappreciated heterogeneity of effect sizes: implications for power, precision, planning of research, and replication","volume":"5","author":"Kenny","year":"2019","journal-title":"Psychol Methods"},{"key":"2024103012174287100_CIT0051","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/jac\/dku553","article-title":"Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients","volume":"5","author":"Heinrich","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2024103012174287100_CIT0052","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.3390\/ijms20122868","article-title":"Opportunities for overcoming mycobacterium tuberculosis drug resistance: emerging mycobacterial targets and host-directed therapy","volume":"20","author":"Torfs","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2024103012174287100_CIT0053","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1183\/09031936.00173608","article-title":"Poverty and tuberculosis: is it truly a simple inverse linear correlation?","volume":"4","author":"Marais","year":"2009","journal-title":"Eur Resp J"},{"key":"2024103012174287100_CIT0054","doi-asserted-by":"crossref","first-page":"e2014070","DOI":"10.4084\/mjhid.2014.070","article-title":"Tuberculosis: epidemiology and control","volume":"1","author":"Sulis","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2024103012174287100_CIT0055","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/2047-783X-15-3-93","article-title":"HAART and the liver: friend or foe?","volume":"3","author":"Pineda","year":"2010","journal-title":"Eur J Med Res"},{"key":"2024103012174287100_CIT0056","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1164\/rccm.201311-2106PP","article-title":"Tuberculosis, pulmonary cavitation, and matrix metalloproteinases","volume":"1","author":"Ong","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2024103012174287100_CIT0057","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1183\/09031936.00124614","article-title":"Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey","volume":"4","author":"G\u00fcnther","year":"2015","journal-title":"Eur Respir J"},{"key":"2024103012174287100_CIT0058","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO\u2019s new end TB strategy","volume":"9979","author":"Uplekar","year":"2015","journal-title":"Lancet"},{"key":"2024103012174287100_CIT0059","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijid.2020.05.082","article-title":"Shorter antibiotic regimens impact the control efforts in high tuberculosis burden regions of Taiwan","author":"Lin","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2024103012174287100_CIT0060","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1186\/s12879-016-2064-3","article-title":"Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis","volume":"1","author":"Gomez","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2024103012174287100_CIT0061","first-page":"CD000970","article-title":"Fully intermittent dosing with drugs for treating tuberculosis in adults","volume":"4","author":"Mwandumba","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"volume-title":"Guidelines for treatment of drug-susceptible tuberculosis and patient care","year":"2017","author":"WHO","key":"2024103012174287100_CIT0062"},{"key":"2024103012174287100_CIT0063","first-page":"CD009913","article-title":"Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis","volume":"5","author":"Gallardo","year":"2016","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/74\/6\/905\/60218783\/rgac004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/74\/6\/905\/60218783\/rgac004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T17:06:39Z","timestamp":1730307999000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/74\/6\/905\/6556348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":63,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgac004","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"type":"print","value":"0022-3573"},{"type":"electronic","value":"2042-7158"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,6,1]]}}}